ORAL PRESENTATION



Open Access

Cyclic CMP and cyclic UMP: new (old) second messengers

Roland Seifert^{1*}, Kerstin Beste¹, Heike Burhenne¹, Ulrike Voigt¹, Sabine Wolter¹, Andreas Hammerschmidt¹, Daniel Reinecke¹, Peter Sandner², Andreas Pich³, Frank Schwede⁴, Hans G Genieser⁴, Volkhard Kaever¹

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany. 24-26 June 2011

Historical background


As early as 1965 it was proposed that in addition to the well-established second messengers, cyclic AMP and cyclic GMP, the cyclic pyrimidine nucleotides, cyclic CMP (cCMP) and cyclic UMP (cUMP) could play a role as second messenger molecules. This hypothesis was based on the identification of cCMP- and cUMP-hydrolyzing phosphodiesterase (PDE) activities in mammalian tissues [1,2]. Additionally, extracellular effects of cCMP on cell proliferation were reported [3], but unfortunately, those effects were not reproduced. Moreover, a specific cytidylyl cyclase activity was proposed, but the methodology used was questionable [4,5]. Furthermore, cCMP and cUMP were supposedly identified by fast atom bombardment mass spectrometry, but the methodology was not sufficiently accurate for unequivocal mass determination of cCMP and cUMP [6]. Because of the substantial methodological problems, the cCMP and cUMP field had been largely abandoned. Our recent discovery that the bacterial "adenylyl" cyclase toxins, CyaA from Bordetella pertussis and edema factor from Bacillus anthracis, also exhibit substantial cytidylyl- and uridylyl cyclase activity as assessed by radiometric assays [7], renewed interest in the cCMP and cUMP field.

Methodology

In order to critically re-evaluate the cCMP- and cUMP field, we developed highly sensitive quantitative HPLC-MS/MS mass spectrometry methods to detect multiple cyclic nucleotides (cNMPs). Unequivocal detection of cNMPs was achieved by determination of the accurate mass of the intact cNMPs and defined cNMP fragments. The MS methodology allowed us to determine cNMP

* Correspondence: seifert.roland@mh-hannover.de

¹Institute of Pharmacology, Hannover Medical School, Germany Full list of author information is available at the end of the article



Results and discussion

Taking advantage of the HPLC-MS/MS methodology, we detected cCMP and cUMP in numerous cultured cell types and in human urine. Growth-arrest of cells resulted in preferential decrease of cellular cCMP- and cUMP concentrations as compared to cAMP- and cGMP concentrations, indicating that cCMP- and cUMP production is dependent on factors present in serum. Known adenylyl and guanylyl cyclases exhibit, to different extents, cytidylyl- and uridylyl cyclase activities. The cNMP agarose affinity chromatography technique identified cAMP-dependent protein kinase as one target protein for cCMP and cUMP, these cNMPs being lowaffinity activators of this kinase. Moreover, several recombinant cAMP- and cGMP-degrading PDEs were identified to exhibit cUMP-degrading activity, whereas to this end, we have not been able to identify a cCMPhydrolyzing PDE. Finally, cCMP- and cUMP-acetoxymethylesters are capable of inducing differentiation of neuronal cells. In conclusion, (i) cCMP and cUMP are present at substantial concentrations in various cells types, (ii) cCMP- and cUMP concentrations are regulated by the cell proliferation status, (iii) cUMP is degraded by known PDEs, and (iv) biological effects of cCMP and cUMP are beginning to be unmasked. All these data are indicative for a role of cCMP and cUMP as (old) new second messenger molecules.



© 2011 Seifert et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author details

¹Institute of Pharmacology, Hannover Medical School, Germany. ²Bayer HealthCare, Pharma Research Center, Wuppertal, Germany. ³Institute of Toxicology, Hannover Medical School, Germany. ⁴Biolog Life Science Institute, Bremen, Germany.

Published: 1 August 2011

References

- Hardman JG, Sutherland EW: A cyclic 3',5'-nucleotide phosphodiesterase from heart with specificity for uridine 3',5'-phosphate. J Biol Chem 1965, 240:3704-3705.
- Helfman DM, Shoji M, Kuo JF: Purification to homogeneity and general properties of a novel phosphodiesterase hydrolyzing cyclic CMP and cyclic AMP. J Biol Chem 1981, 256:6327-6334.
- Bloch A, Dutschman G, Maue R: Cytidine 3',5'-monophosphate (cyclic CMP). II. Initiation of leukemia L-1210 growth in vitro. *Biochem Biophys Res Commun* 1974, 59:955-959.
- Cech SY, Ignarro L: Cytidine 3',5'-monophosphate (cyclic CMP) formation in mammalian tissues. Science 1977, 198:1063-1065.
- Gaion RM, Krishna G: Cytidylate cyclase: the product isolated by the method of Cech and Ignarro is not cytidine 3',5'monophosphate. Biochem Biophys Res Commun 1979, 86:105-111.
- Newton RP, Salih SG, Kingston EE: Extraction, purification and identification of cytidine 3',5'-cyclic monophosphate from rat tissues. *Biochem J* 1984, 221:665-673.
- Göttle M, Dove S, Kees F, Schlossmann J, Geduhn J, König B, Shen Y, Tang WJ, Kaever V, Seifert R: Cytidylyl and uridylyl cyclase activity of Bacillus anthracis edema factor and Bordetella pertussis CyaA. *Biochemistry* 2010, 49:5494-5503.

doi:10.1186/1471-2210-11-S1-O34

Cite this article as: Seifert *et al.*: Cyclic CMP and cyclic UMP: new (old) second messengers. *BMC Pharmacology* 2011 11(Suppl 1):O34.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit